A5027243725- Psoriasis: Treatment and Pathogenesis
- Pharmacogenetics and Drug Metabolism
- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- Inflammatory mediators and NSAID effects
- Pharmaceutical studies and practices
- Cytokine Signaling Pathways and Interactions
- Acute Ischemic Stroke Management
- Immunodeficiency and Autoimmune Disorders
- Eicosanoids and Hypertension Pharmacology
- Autoimmune and Inflammatory Disorders Research
- Cerebrovascular and Carotid Artery Diseases
- Spondyloarthritis Studies and Treatments
- Biosimilars and Bioanalytical Methods
- Mast cells and histamine
- Health Systems, Economic Evaluations, Quality of Life
- Stroke Rehabilitation and Recovery
- Rheumatoid Arthritis Research and Therapies
- SARS-CoV-2 and COVID-19 Research
- Immune responses and vaccinations
- Autoimmune Bullous Skin Diseases
- Animal Virus Infections Studies
- Acute Lymphoblastic Leukemia research
- Epigenetics and DNA Methylation
- Inflammatory Bowel Disease
Hospital Universitario La Paz
2024
Universidad Autónoma de Madrid
2013-2024
Hospital Universitario de La Princesa
2012-2020
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2012
Instituto de Salud Carlos III
2012
Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs metabolized by CYP2C9. The aim of this study is evaluate the possible association between sex, polymorphisms in <i>CYP2C8</i> and <i>CYP2C9</i> genes, pharmacokinetics losartan, valsartan, candesartan, telmisartan. population comprised 246 healthy volunteers from seven single-dose clinical trials: 64 two candesartan studies, 43 a telmisartan study, 36 losartan 103 three valsartan studies. DNA was extracted...
Psoriasis improves when IL-17 is blocked. Anti-TNF drugs reduce the signaling pathway, and anti-IL-17 are being developed to treat moderate-to-severe psoriasis. We analyzed three SNPs in IL-17A (rs2275913 rs10484879) IL-17F (rs763780) look for an association with psoriasis and/or response anti-TNF or ustekinumab. included 197 healthy controls 194 patients The results of univariate analysis showed between rs10484879 psoriasis, although this relationship disappeared after adjustment HLA-C...
Celecoxib is metabolized by enzymes of the cytochrome P450 (CYP450) superfamily, mainly CYP2C9 and CYP3A4. Polymorphisms in gene have been associated with decreased enzyme activity alteration celecoxib pharmacokinetic parameters. However, literature reports are limited, some results contradictory. We enrolled 24 healthy volunteers a single-dose replicated crossover trial 200 mg. evaluated association between single-nucleotide polymorphisms CYP2C8 genes (CYP2C8*2, CYP2C8*3, CYP2C8*4,...
Aim: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept. Materials & methods: We association between 124 polymorphisms response to etanercept moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 treatment 68). Results: The results multivariate analysis showed an rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) months. Besides rs928655 (GBP6) rs2546890 (IL12B) were associated Conclusions....
To evaluate the effect of polymorphisms in CYP2C9 and CYP2C8 gender on pharmacokinetics enantiomeric forms ibuprofen.122 healthy volunteers were genotyped for CY2C8 using real-time PCR.CYP2C8 affected neither R- nor S-ibuprofen. CYP2C9*3 CYP2C9*2 carriers had a lower S-ibuprofen clearance higher AUC half-life. R-ibuprofen was decreased carriers. Gender pharmacokinetics. Multiple regression analysis showed that CYP2C9*2, associated with clearance, but only clearance.The is by gender. do not...
Aim: To evaluate the possible association between polymorphisms in CYP2C19 and pharmacokinetics of omeprazole, rabeprazole pantoprazole. Materials & methods: 151 healthy volunteers were evaluated for gene using real-time polymerase chain reaction. Plasma concentrations measured high-performance liquid chromatography coupled to mass spectrometry. Results: Carriers *2 allele displayed poor metabolism all PPIs studied (around 50% decrease clearance). Subjects with *17 showed a light increase...
Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We 121 polymorphisms to study a possible association between these SNPs and response ustekinumab (PASI75 at 4 months; n = 69). Results/Conclusion: The adjusted results (false discovery rate) showed an five TNFRSF1A, HTR2A, NFKBIA, ADAM33 IL13 genes, poor Furthermore, six CHUK, C17orf51, ZNF816A, STAT4, SLC22A4 Corf72 genes were associated better However, there...
This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab.Prospective observational evaluating association 124 polymorphisms response to or infliximab (PASI75) moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 treatment 90). Significant SNPs for univariate analysis were subjected multivariate analysis.Five associated PASI75 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) rs645544...
Psoriasis is a chronic skin disease in which genetics play major role. Although many genome-wide association studies have been performed psoriasis, knowledge of the age at onset remains limited. Therefore, we analyzed 173 single-nucleotide polymorphisms genes associated with psoriasis and other autoimmune diseases patients moderate-to-severe plaque type I (early-onset, <40 years) or II (late-onset, ≥40 healthy controls. Moreover, comparison between psoriasis. Our stratified population (n =...
Association between psoriasis and polymorphisms in the TNF, IL12B, IL23R genes Spanish patientsBackground & Objectives: Susceptibility to has been associated with HLA-C*0602 allele, although it may be affected by other polymorphisms.Materials Methods: We genotyped 142 patients 160 healthy volunteers evaluate possible relationship susceptibility allele genes.Results: The frequency of wild-type TNF-238, TNF-308, TNF-1031 genotypes was greater than volunteers, that mutant TNF-857 genotype...
While anti-TNF therapies are effective against psoriasis, 30%-50% of patients do not show an adequate response to these drugs. Different candidate-gene pharmacogenetics studies have identified single nucleotide polymorphisms that may predict drugs in psoriasis. Nevertheless, only one paper has undertaken a pharmacogenomic approach failing find significant biomarkers biological drug along the whole genome. Furthermore, most pharmacogenetic candidate previously been confirmed different cohort...
CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes were to assess humoral against SARS-CoV-2, 28 days after third dose mRNA vaccine, in subjects that received previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary extended 3 and 6 months. mRNA-1273 naive participants previously vaccinated regimen reached higher neutralizing antibodies titers variants concern Delta BA.1 lineage Omicron compared...
Background: Psoriasis is a skin disease characterized by the presence of erythematous, scaly plaques on extensor surfaces body. Treatment varies according to stage disease, with most severe cases being treated biologic treatments that differ in efficacy and persistence over time. This study aimed evaluate 10-year drugs (adalimumab, etanercept, infliximab ustekinumab) treatment moderate-to-severe plaque psoriasis. Methods: A total 143 patients (61 women 82 men) were evaluated; data collected...